Share：
Share this content in WeChat
X
[Chinese][PDF]87785
• Review •
MR contrast media of liver: the past, present and future
ZHANG Shui-xing  LIU Yu-bao  LIANG Chang-hong 

DOI:10.3969/j.issn.1674-8034.2012.01.014.


[Abstract] MR contrast media has been widely used in the diagnosis and researches of liver lesions. For a further understanding, the past and the present status of contrast media used in liver MRI are reviewed, focused on the medical diagnosis and researches. The perspective is also discussed.
[Keywords] Liver；Magnetic resonance imaging；Contrast media

ZHANG Shui-xing Department of Radiology, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, China

LIU Yu-bao Department of Radiology, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, China

LIANG Chang-hong * Department of Radiology, Guangdong General Hospital (Guangdong Academy of Medical Sciences), Guangzhou 510080, China

*Correspondence to: Liang CH, E-mail: cjr.lchh@vip.163.com

Conflicts of interest   None.

Received  2011-10-03
Accepted  2011-12-30
DOI: 10.3969/j.issn.1674-8034.2012.01.014
DOI:10.3969/j.issn.1674-8034.2012.01.014.

[1]
Semelka RC, Helmberger TK. Contrast agents for MR imaging of the liver. Radiology, 2001, 218(1): 27-38.
[2]
Juluru K, Vogel-Claussen J, Macura KJ, et al. MR imaging in patients at risk for devoloping nephrogenic systemic fibrosis: protocols, practices, and imaging techniques to maximize patient safety. Radiographics, 2009, 29(1): 9-22.
[3]
Thomsen HS, Marckmann P, Logager VB. Update on Nephrogenic Systemic Fibrosis. Magn Reson Imaging Clin N Am, 2008, 16 (4): 551-560.
[4]
Schuhmann-Giamperi G, Schmitt-Willich H, Press WR, et al. Preclinical evaluation of Gd-EOB-DTPA as a contrast agent in MR imaging of the hepatobiliary system. Radiology, 1992, 183(1): 59-64.
[5]
Vittadini G, Felder E, Tirone P, et al. B-19036, a potential new hepatobiliary contrast agent for MR proton imaging. Invest Radiol, 1988, 23(Supp 1): S246-S248.
[6]
Duda S, Laniado M, Kopp A, et al. Superparamagnetic iron oxide: detection of focal liver lesions at high-field-strength MR imaging. JMRI, 1994, 4(3): 309-314.
[7]
Saito K, Shindo H, Ozuki T, et al. Perfusion study hypervascular hepatocellular carcinoma with SPIO. Magnetic Resonance in Medical Sciences, 2005, 4(4): 151-158.
[8]
Kopp AF, Laniado M, Dammann F, et al. MR imaging of the liver with Resovist: Safty, efficacy, and pharmacodynamic properties. Radiology, 1997, 204(3): 749-756.
[9]
张水兴，梁长虹，黄飚. 对比剂铁羧葡胺在正常兔MR脑灌注初步实验研究. 中华放射学杂志, 2008, 42(3): 309-313.
[10]
Rockall AG, Planche K, Power N, et al. Detection of neuroendocrine liver metastases with MnDPDP-enhanced MRI. Neuroendocrinology, 2009, 89(3):288-295.
[11]
Seale MK, Catalano OA, Saini S, et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics, 2009, 29(6):1725-1748.
[12]
Kim JH, Kim MJ, Park YN, et al. Mangafodipir trisodium-enhanced MRI of hepatocellular carcinoma: correlation with histological characteristics. Clin Radiol, 2008, 63(11): 1195-1204.
[13]
刘燕丽，宦怡，葛雅丽, 等. Mn-DPDP的MR增强扫描在肝脏病变中的应用. 第四军医大学学报, 2004, 25(4): 351-354.
[14]
Ni Y, Petre C, Miao Y, et al. Magnetic resonance imaging histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol, 1997, 32(12): 770-779.
[15]
Ni Y, Cresens E, Adriaens P, et al. Exploring multifunctinal features of necrosis avid contrast agents. Acad Radiol, 2002, 9 (Suppl 2): S488-S490.
[16]
Schmiedl UP, Nelson JA, Robinson DH, et al. Pharmaceutical properties, biodistribution, and imaging characteristics of manganese-mesoporphyrin. A potential hepatobiliary contrast agent for magnetic resonance imaging. Invest Radiol, 1993, 28(10): 925-932.
[17]
Mikawa M, Kato H, Okumura M, et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem, 2001, 12(4): 510-514.
[18]
卢兴，徐建勋，施祖进, 等. 新型核磁成像对比剂──两种Gd@C82水溶性衍生物的弛豫性能研究. 高等学校化学学报, 2004, 25(4): 697-700.
[19]
Kabalka G, Buonocore E, Hubner K, et al. Gadolinium labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology, 1987, 163(4): 255-258.
[20]
Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. FASEB J. 2005, 19(3): 311-330.
[21]
Corot C, Robert P, Lancelot E, et al. Tumor imaging using P866, a high-relaxivity gadolinium chelate designed for folate receptor targeting. Magn Reson Med, 2008, 60(6): 1337-1346.
[22]
Corbin IR, Li H, Chen J, et al. Low-density lipoprotein nanoparticles as magnetic resonance imaging contrast agents. Neoplasia, 2006, 8(6): 488-498.
[23]
Ozaki N, Sankar AU, Yamashita M, et al. Synthesis, in vitro and in vivo studies of Gd-DTPA-XDA-D1-Glc (OH) complex as a new potential MRI contrast agent. Bioorg Med Chem Lett, 2010, 20(3): 932-934.

PREV Atypica pial neurocysticercosis: one cases report
NEXT Functional MRI in neuropsychiatric disorders
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn